PerkinElmer, Inc. and Verinata Health, Inc. Announce Collaboration to Expand Access to Non-Invasive Prenatal Test for Down Syndrome and Other Chromosomal Abnormalities
Published: Jan 09, 2013
WALTHAM, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) and Verinata Health, Inc., today announced a strategic agreement for expanding access to Verinata’s verifi® test, the most comprehensive non-invasive prenatal test (NIPT) currently available for high-risk pregnancies. The verifi® test, which is performed at Verinata’s CLIA-certified, California laboratory, uses a single maternal blood draw as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies. Chromosomal aneuploidy is an abnormal number of chromosomes.